Patients
Mitobridge is committed to developing medicines that improve mitochondrial function and treat challenging diseases. Operating within the Astellas companies, we put patients first – at the forefront of our work, considering what matters most to them, and involving them in our processes. Keeping patients at the center of what we do is key to delivering optimal value to those who are living with the diseases we seek to treat with our medicines.
Below you will find more information about diseases we are targeting and resources for patients.
ASP1128 for Acute Kidney Injury
Disease with unmet need
Acute kidney injury (AKI) is a sudden loss of kidney function that often occurs in hospitalized patients as a result of cardiac and/or vascular surgery or other trauma or infection.
New treatment approach
We are developing ASP1128, a potentially first-in-class investigational medicine for the treatment of AKI. ASP1128 is believed to have protective effects of kidney cells in stressful situations of AKI by promoting fatty acid oxidation in the mitochondria.
Learn moreClinical trial
A proof of concept Phase 2 clinical study with ASP1128 is ongoing. Information about the trial and participating centers can be found at Clinicaltrials.gov (identifier: NCT03941483).
Resources in the treatment community
ASP0367 for Duchenne Muscular Dystrophy
Disease with unmet need
Duchenne Muscular Dystrophy (DMD) is a rare genetic disease that causes progressive muscle degeneration and weakness due to alterations of a protein called dystrophin. With onset in early childhood, this debilitating fatal disorder affects primarily boys and leads to progressive cardiac, skeletal and smooth muscle weakness and eventual loss of muscle mass.
New treatment approach
We are developing ASP0367, a mitochondrial-directed investigational medicine for the treatment of DMD, which is designed to treat DMD by increasing fatty acid oxidation and mitochondrial biogenesis in muscle cells.
Learn moreClinical trial
A Phase 1b clinical study with ASP0367, is scheduled to evaluate safety and efficacy in DMD patients starting in early 2020. Information about the trial and participating centers can be found at Clinicaltrials.gov (identifier: NCT04184882).
Resources in the treatment community
ASP0367 for Primary Mitochondrial Myopathies
Disease with unmet need
Primary Mitochondrial Myopathies (PMM) is a complex mitochondrial disease in which genetic mutations primarily impair the function of mitochondria, resulting in reduced muscle function, reduced endurance to exercise, increased fatigue, and muscle atrophy. In addition, PMM may present serious and life-threatening health conditions due to multiple organ involvement. For example, decreased myocardial function may lead to cardiomyopathy and heart failure. Decreased function of respiratory muscles may cause respiratory failure and pneumonia.
New treatment approach
There is no FDA-approved treatment for PMM, a rare disease with a high unmet medical need. We are developing ASP0367, an oral mitochondrial-directed investigational medicine that may improve exercise intolerance and fatigue in patients with PMM.
Learn moreClinical trial
The MOUNTAINSIDE program includes a pivotal Phase 2/3 clinical trial that is enrolling adult patients with PMM at 14 sites in the U.S. Information about the trial and participating centers can be found at Clinicaltrials.gov (identifier: NCT04641962).
Resources in the treatment community
